Lv1
40 积分 2023-06-25 加入
The prognostic value of CLDN18.2 expression in pancreatic ductal adenocarcinoma: a systematic review and individual patient data meta-analysis
1小时前
待确认
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2小时前
已完结
皖公网安备34019202002308
